Timing of Colorectal Cancer Screening: How Current Guidelines Vary

Slideshow

This slideshow reviews the latest guidelines and updates on colorectal cancer screening.

The American Cancer Society (ACS) estimates that, in 2019 alone, there will be more than 100,000 new diagnoses of colon cancer and more than 44,000 new cases of rectal cancer in the United States. Clinicians require up-to-date information on colorectal cancer screening guidelines to provide care to their patient populations. This slideshow summarizes the last recommendations from various professional organizations as well as the available screening strategies. 

Recent Videos
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
Almost all patients evaluable for efficacy reported a decrease in ctDNA when treated with daraxonrasib for RAS-mutant pancreatic ductal adenocarcinoma.
Additional progression-free survival data from the phase 3 BREAKWATER trial will be presented at future meetings.
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Related Content
Regorafenib/Sintilimab Show Tolerability and Mixed Efficacy in MSS mCRC

Regorafenib/Sintilimab Show Tolerability and Mixed Efficacy in MSS mCRC

Tim Cortese
February 17th 2025
Article

Efficacy results demonstrated by regorafenib and sintilimab in patients with mSS mCRC were dependent on patient characteristics such location of metastasis and RAS type.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Encorafenib Combo Improves PFS in Metastatic Colorectal Cancer

Encorafenib Combo Improves PFS in Metastatic Colorectal Cancer

Tim Cortese
February 3rd 2025
Article

Full progression-free survival results for patients with BRAF V600E mCRC from the phase 3 BREAKWATER trial will be presented at an upcoming medical conference.

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval

Jagoda Misniakiewicz, PharmD
June 10th 2024
Podcast

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Findings from the CheckMate 9DW trial support the CHMP’s recommendation for approving nivolumab/ipilimumab for those with unresectable HCC.

Nivolumab Combo Earns Positive CHMP Opinion in Advanced Liver Cancer

Russ Conroy
February 1st 2025
Article

Findings from the CheckMate 9DW trial support the CHMP’s recommendation for approving nivolumab/ipilimumab for those with unresectable HCC.

Data from 2025 ASCO GI support the potential role that combinations such as nivolumab/ipilimumab may play a part in managing different types of GI cancers.

Top 5 Takeaways for Gastrointestinal Cancer Management From 2025 ASCO GI

Russ Conroy
January 30th 2025
Article

Data from 2025 ASCO GI support the potential role that combinations such as nivolumab/ipilimumab may play a part in managing different types of GI cancers.